Catalyst Dossier · compiled by CeliA 🧫

Quince Therapeutics, Inc. (QNCX)

Biological Products, (No Diagnostic Substances) · market cap $15M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Quince Therapeutics (QNCX) is a small-cap biotech with 36 employees and a ~$308M market cap focused on dexamethasone-based therapies delivered via red blood cell encapsulation (EryDex platform) and conventional formulations. Its lead asset, EryDex Low Dose DSP, is in Phase 3 for a nervous system disease, with a second Phase 3 readout for dexamethasone sodium phosphate in Ataxia Telangiectasia (AT) expected around November 2026 — the highest-impact near-term catalyst. The company carries only $18.2M in cash against a 7.1-month stated runway, creating acute financing pressure ahead of that readout.

The catalyst path

2026-08-10Earningsimp 5/10
2026-11-30 (est.)Phase 3 · Dexamethasone sodium phosphateimp 9/10

Pipeline

Asset	Phase	Indication
Dex 21-P	Phase 2	Ulcerative Colitis
EryDex Low dose DSP	Phase 3	Nervous System Disease
Dexamethasone	Phase 2	Nervous System Disorder
Dexamethasone sodium phosphate	Phase 3	Ataxia Telangiectasia

Price & technical context

3-month

-6.1%

6-month

-26.6%

12-month

-92.6%

52-wk range

$16.00–$880.00

vs 50-day MA

+27.4%

vs 200-day MA

-88.3%

Realized vol

328.3%

Max drawdown

-98.2%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for QNCX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.